뇌졸중 역학 분석과 예측(2026년)

The global stroke prevelance is projected to grow at a CAGR of 1.5% during the forecast period, increasing from USD 98.8 million patients in 2026 to USD 112.8 million patients by 2035.

Stroke remains the second leading cause of death and the third leading cause of disability worldwide, with the majority of the disease burden occurring in low- and middle-income countries.

Stroke encompasses ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and transient ischemic attack (TIA). Ischemic stroke accounts for nearly 85% of all stroke cases globally and remains the primary focus of epidemiological research and therapeutic development. Epidemiology analysis provides valuable insights into patient populations, demographic distribution, disease progression, mortality trends, risk factors, healthcare burden, and regional variations that support strategic decision-making for pharmaceutical companies, healthcare providers, researchers, and policymakers.

Market Drivers

Increasing Global Burden of Stroke

The number of stroke cases continues to rise because of population aging, increasing life expectancy, hypertension, diabetes, obesity, atrial fibrillation, smoking, and sedentary lifestyles. Although age-standardized rates have declined in many countries, the absolute number of stroke cases, deaths, and survivors continues to increase worldwide.

Growing Need for Population Health Data

Healthcare systems, pharmaceutical companies, and public health organizations increasingly rely on epidemiological data to improve disease surveillance, allocate healthcare resources, identify high-risk populations, and support clinical research and market access strategies.

Expansion of Stroke Prevention Programs

Governments and healthcare organizations continue investing in hypertension control, diabetes management, smoking cessation, healthy lifestyle promotion, and early diagnosis programs aimed at reducing stroke incidence and improving long-term outcomes.

Rising Investment in Neurological Research

Growing research activity focused on stroke prevention, early diagnosis, precision medicine, and rehabilitation continues to increase demand for high-quality epidemiological datasets supporting clinical development and healthcare policy.

Market Restraints

Underdiagnosis in Developing Countries

Limited access to neurological care, inadequate diagnostic infrastructure, and inconsistent disease reporting contribute to underestimation of stroke prevalence in several low- and middle-income countries.

Variability in Data Collection

Differences in national registries, healthcare systems, disease classification, and surveillance methodologies create variability in epidemiological estimates across regions.

Healthcare Access Disparities

Socioeconomic inequalities continue to influence diagnosis rates, treatment access, rehabilitation services, and survival outcomes, particularly in resource-limited settings.

Epidemiology Insights

The global stroke epidemiology can be segmented by stroke type, age group, gender, risk factor, disease severity, and geography.

By stroke type, the epidemiology includes ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and transient ischemic attack (TIA). Ischemic stroke represents the largest proportion of diagnosed cases worldwide, while hemorrhagic stroke contributes disproportionately to mortality despite its lower incidence.

By age group, stroke incidence increases substantially with advancing age. Adults aged 65 years and older account for the largest patient population, although the incidence of stroke among younger adults is gradually increasing because of obesity, diabetes, hypertension, and lifestyle-related risk factors.

By gender, stroke affects both men and women, with incidence generally higher among men at younger ages, while women experience a greater lifetime risk because of longer life expectancy and age-related disease burden. Women also account for a substantial proportion of stroke-related mortality in older age groups.

By risk factor, major contributors include hypertension, diabetes mellitus, atrial fibrillation, dyslipidemia, obesity, smoking, excessive alcohol consumption, physical inactivity, unhealthy diet, and environmental exposures. Hypertension remains the single most important modifiable risk factor for stroke worldwide.

Geographically, epidemiological analysis evaluates disease burden across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, highlighting differences in incidence, prevalence, mortality, disability-adjusted life years (DALYs), healthcare access, and treatment availability.

Epidemiological Trends

The global stroke epidemiology continues to evolve because of demographic and lifestyle changes.

Key trends include:

• Increasing absolute number of stroke cases worldwide.
• Growing prevalence among aging populations.
• Rising incidence associated with hypertension, diabetes, and obesity.
• Greater disease burden in low- and middle-income countries.
• Improved survival resulting in higher numbers of stroke survivors requiring long-term care.
• Increasing use of national stroke registries and real-world epidemiological databases.
• Expansion of precision epidemiology through artificial intelligence and digital health technologies.

Regional Insights

North America maintains extensive epidemiological surveillance supported by comprehensive stroke registries, advanced healthcare infrastructure, and widespread access to diagnostic imaging. Continued improvements in acute stroke care have reduced mortality while increasing the number of long-term stroke survivors.

Europe continues to benefit from established national stroke registries, coordinated prevention programs, and strong public health initiatives. Several European countries have reported declining age-standardized stroke rates despite increasing absolute case numbers due to population aging.

Asia-Pacific accounts for one of the largest global stroke populations because of its large and aging population base. China, India, and Japan contribute significantly to the regional disease burden, while rapid urbanization and increasing cardiovascular risk factors continue to drive new stroke cases.

Latin America and the Middle East & Africa continue to experience increasing stroke incidence because of demographic transition, expanding cardiovascular risk factors, and improving diagnosis. Continued healthcare investment is expected to enhance epidemiological surveillance and disease management across these regions.

Competitive Landscape

The stroke epidemiology landscape involves healthcare organizations, epidemiology research firms, academic institutions, government agencies, pharmaceutical companies, and public health organizations.

Organizations continue investing in large-scale population studies, disease registries, real-world evidence, artificial intelligence-assisted analytics, and longitudinal epidemiological databases. Strategic collaborations between academic institutions, healthcare providers, pharmaceutical companies, and government agencies continue to improve understanding of stroke burden and support clinical development.

Future Outlook

The future of stroke epidemiology analysis will be driven by advances in digital health, artificial intelligence, precision medicine, genomic epidemiology, and real-world evidence generation. Improved disease surveillance, standardized reporting systems, and integration of electronic health records will provide more accurate estimates of stroke incidence, prevalence, mortality, and long-term outcomes.

Increasing global collaboration, expanded national stroke registries, and improved access to healthcare data are expected to strengthen epidemiological research while supporting prevention programs, therapeutic innovation, and healthcare resource planning through 2035.

Conclusion

The Global Stroke Epidemiology Analysis demonstrates the growing worldwide burden of stroke driven by aging populations, increasing cardiovascular risk factors, and changing demographic patterns. Although improvements in prevention, diagnosis, and acute treatment have reduced age-standardized mortality in many regions, the overall number of stroke cases and survivors continues to rise. Comprehensive epidemiological analysis will remain essential for healthcare planning, clinical research, pharmaceutical development, and public health policy aimed at reducing the global impact of stroke.

Key Benefits of this Report

• Comprehensive analysis of global stroke incidence, prevalence, mortality, and patient populations.
• Detailed assessment of demographic trends, disease burden, and regional epidemiology.
• Insights into major risk factors, disease progression, and healthcare utilization.
• Evaluation of epidemiological trends supporting clinical development and market planning.
• Valuable resource for pharmaceutical companies, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Patient population assessment, epidemiology forecasting, market opportunity analysis, clinical trial planning, healthcare resource allocation, competitive intelligence, commercial strategy development, investment analysis, and public health planning.

Report Coverage

• Historical epidemiological data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of global stroke epidemiology by stroke type, age group, gender, risk factor, disease severity, and geography
• Evaluation of incidence, prevalence, mortality, diagnosed patient population, disability burden, survival trends, and epidemiological forecasts
• Assessment of regional disease burden, healthcare utilization, demographic trends, and unmet medical needs
• Analysis of major risk factors, population trends, epidemiological modeling, and future disease burden projections through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings
• 1.3 Global Stroke Epidemiology Snapshot
  • 1.3.1 Incidence Overview
  • 1.3.2 Prevalence Overview
  • 1.3.3 Mortality and Disability Burden
• 1.4 Key Epidemiology Trends
• 1.5 Forecast Highlights (2025-2035)
• 1.6 Strategic Insights

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Stroke
  • 2.1.1 Definition and Clinical Overview
  • 2.1.2 Disease Burden and Public Health Impact
  • 2.1.3 Risk Factors and Disease Progression
• 2.2 Stroke Classification
  • 2.2.1 Ischemic Stroke
  • 2.2.2 Hemorrhagic Stroke
    • 2.2.2.1 Intracerebral Hemorrhage (ICH)
    • 2.2.2.2 Subarachnoid Hemorrhage (SAH)
  • 2.2.3 Transient Ischemic Attack (TIA)
• 2.3 Etiology and Pathophysiology
  • 2.3.1 Atherosclerosis and Large Vessel Disease
  • 2.3.2 Cardioembolic Stroke
  • 2.3.3 Small Vessel Disease
  • 2.3.4 Genetic and Lifestyle Factors
• 2.4 Epidemiology Analysis
  • 2.4.1 Global Incidence Analysis
  • 2.4.2 Global Prevalence Analysis
  • 2.4.3 Age-wise Epidemiology
  • 2.4.4 Gender-wise Epidemiology
  • 2.4.5 Stroke Subtype-wise Epidemiology
  • 2.4.6 Mortality Analysis
  • 2.4.7 Disability-Adjusted Life Years (DALYs)
  • 2.4.8 Recurrence Rate Analysis
  • 2.4.9 Epidemiology Forecast (2025-2035)

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Rising Aging Population
  • 3.2.2 Increasing Burden of Cardiovascular Diseases
  • 3.2.3 Growing Awareness and Early Diagnosis
  • 3.2.4 Expansion of Stroke Care Infrastructure
• 3.3 Market Restraints
  • 3.3.1 Limited Access in Low-Income Regions
  • 3.3.2 High Cost of Acute Stroke Treatment
  • 3.3.3 Delayed Diagnosis and Treatment
• 3.4 Market Opportunities
  • 3.4.1 AI-Based Stroke Diagnosis
  • 3.4.2 Expansion of Tele-Stroke Networks
  • 3.4.3 Neuroprotective Therapies Development
  • 3.4.4 Biomarker-Based Precision Medicine
• 3.5 Porter's Five Forces Analysis
• 3.6 PESTLE Analysis
• 3.7 Value Chain Analysis

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Reimbursement Landscape
• 4.3 Health Technology Assessment Trends
• 4.4 Pricing Analysis
• 4.5 Patient Access Programs
• 4.6 Insurance Coverage Trends
• 4.7 Stakeholder Analysis

5. Innovation & Pipeline Landscape

• 5.1 Innovation Overview
• 5.2 Emerging Technologies
  • 5.2.1 AI-Assisted Stroke Detection
  • 5.2.2 Digital Therapeutics
  • 5.2.3 Advanced Neuroimaging
  • 5.2.4 Wearable Monitoring Devices
• 5.3 Pipeline Landscape
  • 5.3.1 Phase I Pipeline Candidates
  • 5.3.2 Phase II Pipeline Candidates
  • 5.3.3 Phase III Pipeline Candidates
• 5.4 Pipeline Segmentation by Mechanism of Action
• 5.5 Pipeline Segmentation by Modality
  • 5.5.1 Small Molecules
  • 5.5.2 Biologics
  • 5.5.3 Cell Therapies
  • 5.5.4 Gene Therapies
• 5.6 Clinical Trial Landscape
• 5.7 Patent Analysis
• 5.8 Investment and Funding Trends

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Acute Stroke Management
  • 6.2.1 Intravenous Thrombolysis
  • 6.2.2 Mechanical Thrombectomy
  • 6.2.3 Surgical Interventions
• 6.3 Secondary Stroke Prevention
  • 6.3.1 Antiplatelet Therapy
  • 6.3.2 Anticoagulant Therapy
  • 6.3.3 Lipid-Lowering Therapy
  • 6.3.4 Blood Pressure Management
• 6.4 Rehabilitation and Long-Term Care
• 6.5 Treatment Guidelines and Clinical Practice Trends

7. Global Stroke Epidemiology Report Size & Forecast

• 7.1 Global Market Overview
• 7.2 Historical Market Size Analysis (2021-2025)
• 7.3 Market Forecast (2026-2035)
• 7.4 Market Attractiveness Analysis
• 7.5 Incremental Growth Opportunities

8. Global Stroke Epidemiology Report Segmentation

• 8.1 By Stroke Type
  • 8.1.1 Ischemic Stroke
    • 8.1.1.1. Thrombotic
    • 8.1.1.2. Embolic
  • 8.1.2 Hemorrhagic Stroke
  • 8.1.3 Transient Ischemic Attack
  • 8.1.4 Others
• 8.2 By Drug Type
  • 8.2.1 Thrombolytics
  • 8.2.2 Antiplatelets
  • 8.2.3 Anticoagulants
  • 8.2.4 Antihypertensives
  • 8.2.5 Others
• 8.3 By Treatment Type
  • 8.3.1 IV Medication
  • 8.3.2 Endovascular Therapy
  • 8.3.3 Surgical Procedures
    • 8.3.3.1 Mechanical Thrombectomy
    • 8.3.3.2 Carotid Endarterectomy (CEA)
    • 8.3.3.3 Others
• 8.4 By Severity Type
  • 8.4.1 Mild
  • 8.4.2 Moderate
  • 8.4.3 Severe
• 8.5 By Age-Group
  • 8.5.1 Below 20 Years
  • 8.5.2 20 to 50 Years
  • 8.5.3 50 to 70 Years
  • 8.5.4 Older than 70 Years
• 8.6 By End User
  • 8.6.1 Hospitals
  • 8.6.2 Specialty Clinics
  • 8.6.3 Rehabilitation Centers
  • 8.6.4 Others

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Market Size and Growth
  • 9.1.2 Epidemiology Trends
  • 9.1.3 Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Growth
  • 9.2.2 Epidemiology Trends
  • 9.2.3 Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Growth
  • 9.3.2 Epidemiology Trends
  • 9.3.3 Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Growth
  • 9.4.2 Epidemiology Trends
  • 9.4.3 Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Growth
  • 9.5.2 Epidemiology Trends
  • 9.5.3 Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Regulatory Overview
• 11.2 Regulatory Framework in the United States (FDA)
• 11.3 Regulatory Framework in Europe (EMA)
• 11.4 Regulatory Framework in Japan (PMDA)
• 11.5 Regulatory Framework in India (CDSCO)
• 11.6 Regulatory Framework in China (NMPA)
• 11.7 Clinical Trial Regulations
• 11.8 Drug Approval Pathways
• 11.9 Pharmacovigilance Requirements
• 11.10 Healthcare Policies Affecting Stroke Management

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Strategic Developments
  • 12.3.1 Collaborations and Partnerships
  • 12.3.2 Acquisitions and Mergers
  • 12.3.3 Product Launches
  • 12.3.4 Regulatory Approvals
• 12.4 SWOT Analysis
• 12.5 Competitive Positioning Matrix

13. Company Profiles

• 13.1 Genentech
• 13.2 Boehringer Ingelheim
• 13.3 F. Hoffmann-La Roche Ltd
• 13.4 Novartis AG
• 13.5 Bayer AG
• 13.6 Johnson & Johnson
• 13.7 Daiichi Sankyo
• 13.8 Sanofi
• 13.9 Novo Nordisk
• 13.10 AstraZeneca PLC
• 13.11 Merck & Co., Inc.
• 13.12 GlaxoSmithKline plc
• 13.13 Eli Lilly and Company
• 13.14 AbbVie Inc.

14. Future Outlook

• 14.1 Future Epidemiology Trends
• 14.2 Emerging Therapeutic Innovations
• 14.3 Future Regulatory Trends
• 14.4 Digital Health and AI Impact
• 14.5 Market Forecast Scenarios
• 14.6 Strategic Recommendations

15. Methodology

• 15.1 Research Objectives
• 15.2 Study Design
• 15.3 Secondary Research Methodology
• 15.4 Primary Research Methodology
• 15.5 Data Validation and Triangulation
• 15.6 Forecasting Methodology
• 15.7 Assumptions and Limitations
• 15.8 Abbreviations and Definitions